Background {#Sec1}
==========

Pelvic radiotherapy is used to treat approximately 17,000 patients per year in the UK with urological, gynaecological and colorectal malignancies \[[@CR1]\]. For a significant proportion of these patients, pelvic radiotherapy improves survival outcomes. For others, it reduces the risk of pelvic recurrences, which can both cause distressing symptoms and be difficult to manage.

Although contributing to the cure of many pelvic cancer survivors, pelvic radiotherapy is associated with late toxicity, in particular late bowel toxicity. Serious life-threatening toxicity such as bowel obstruction, fistulae and bleeding requiring transfusion occur in 4--10% of patients 5--10 years after treatment \[[@CR2]\]. Furthermore, an important consideration for the growing number of survivors of pelvic cancers is that 50% of patients report late bowel toxicity symptoms which adversely affect their quality of life after pelvic radiotherapy.

Late bowel toxicity is generally attributed to radiation to bowel and rectum and these are considered the organs at risk (OARs). Advanced radiotherapy techniques for pelvic treatments are continually evolving, with the aim of reducing dose to these OARs.

However, to determine whether the dose reductions achieved by these techniques are likely to translate into reduced toxicity for patients requires detailed knowledge of the dose-volume parameters and constraints for these OARs. Once dose-volume constraints are known these can be used to limit the risk of toxicity and potentially allow safe dose escalation with modern delivery techniques.

In 2010 the Quantitative Analysis of Normal Tissue Effects in the Clinic (QUANTEC) review summarised the available dose-volume data for bowel toxicity, with one review focussing on rectum and the other on stomach and bowel. For rectum, an extensively studied OAR, QUANTEC reviewed a large amount of high-quality data and dose-volume constraints for rectum for acute and late toxicity were recommended \[[@CR3]\]. These are commonly incorporated into radiotherapy protocols in clinical practice.

However, for bowel there was a relative paucity of data. QUANTEC reviewed data from six papers which examined the dose-volume relationship of bowel with acute bowel toxicity only \[[@CR4]\]. For late bowel toxicity, there was no detailed dose-volume relationship analysis described. Studies mentioned were trial data detailing the incidence of late bowel toxicity at the dose-fractionations used within each trial, though no specific dose-volume predictors can be derived from this information.

The QUANTEC reviewers suggest that the constraints identified for acute bowel toxicity may be applied for late bowel toxicity however clarify that "this correlation is not established". Further, although QUANTEC examined the peritoneal cavity and small bowel loops as OARs, the potential of other bowel components as OARs for bowel toxicity such as sigmoid, duodenum, ileum and anal canal are not detailed.

In a separate paper by Jackson et al., QUANTEC \[[@CR5]\] highlighted issues which hinder the development of dose-volume constraints and the pooling of results from different studies, including variations in toxicity endpoint definition, statistical standards, and anatomical definitions of OARs. They recommended several criteria to assess the quality of future dose-volume studies and to facilitate meta-analysis of these studies.

With reduction of late bowel toxicity being a prime aim of advanced pelvic radiotherapy techniques, the lack of clear dose-volume constraints in this setting has been acknowledged and more studies have been reported. This study aims to systematically review published studies examining the dose-volume predictors of all components of bowel (excluding rectum) for late bowel toxicity, including a quality assessment of these studies from criteria derived from QUANTEC.

From this review we aim to determine the clinically useful dose-volume constraints for late bowel toxicity which can guide protocols for advanced pelvic radiotherapy techniques.

Methods {#Sec2}
=======

Information sources and search strategy {#Sec3}
---------------------------------------

A systematic search was carried out using Medline, Premedline, Embase, Pubmed and Web of Science on 15th October 2013; Updated searches were performed on 10th November 2014, 3rd September 2015 and 1st May 2017 to ensure all new literature was included. Thesaurus and natural language terms around the concepts of "radiotherapy, radiotherapy injuries, side effects, toxicity, intestines bowel, dose, dose fractionation, dose response relationship" were identified for each database. Duplicate references were removed.

Study selection {#Sec4}
---------------

Eligible studies were English language studies, involving human adult patients treated for any gastrointestinal, urological or gynaecological malignancies with external beam radiotherapy. Studies correlating the dose-volume relationship of any component of bowel from duodenum to anal canal with late bowel toxicity were included, apart from those focussed on the rectum, given that it has already been extensively studied as an OAR. Late toxicity was defined as more than 3 months from completion of radiotherapy.

Excluded studies were review articles and letters, studies involving brachytherapy only, or stereotactic body radiotherapy. Both full text papers and conference abstracts were considered, however studies with insufficient methodological detail to be able to repeat the method on an independent sample of patients were excluded.

All abstracts were independently screened by two reviewers (RJ, EH) for inclusion. Full papers of abstracts were acquired and further assessed for eligibility, with any discrepancies discussed between the two reviewers. The reference lists of all the included papers were hand-searched for additional references.

Data extraction and synthesis of results {#Sec5}
----------------------------------------

Bowel can be defined in several different ways and for the purpose of this review studies were divided into those looking at the whole bowel (including bowel loops and peritoneal cavity), small bowel (and its components) and large bowel (and its components). For each included study the number of patients, proportion with the toxicity, tumour site, OAR studied, toxicity definition, treatment details and key findings were tabulated.

Furthermore, the recommendations from QUANTEC \[[@CR5]\] on quality of dose-volume studies were reviewed, and those criteria that can be applied to this subject were selected (see Table [1](#Tab1){ref-type="table"}). Each included study was assessed for quality against these statistical and endpoint criteria.Table 1Statistical and Endpoint Considerations from QUANTEC \[[@CR5]\]Statistical considerations1 Basic statistical data provided on incidence of toxicity\
 -Both number of subjects and number of events should be reported\
 -If an estimate of incidence is given the standard error should be supplied2 Numerical labeling of response histogram -- if into groups eg. quartiles must state number of patients in each quartile3 When predictive models are correlated with complications parameter estimates must be stated with their standard error4 Complication rates associated with constraints must be reported5 "Goodness of fit" to be reported such as Chi-squared6 Discriminator statistics reported such as receiver operating characteristic curves7 Full organ volumes (rather than partial) should be used\
 -If this is not possible absolute volumes should be used or a standard method of normalization\
 -A clear statement of organ volume definition should be givenToxicity Endpoint considerations1 Symptom-specific information rather than a portmanteau endpoint (eg. RTOG gr 2) should be used2 Consideration that symptoms may be attributed to pre-radiotherapy co-morbidities3 Patient-reporting of symptoms may be important

Results {#Sec6}
=======

Outcomes of the systematic search are shown in Fig. [1](#Fig1){ref-type="fig"}. Overall, 30 studies involving a total of 5126 patients were included as detailed in Table [2](#Tab2){ref-type="table"}. Twenty-one studies included patients with prostate cancer, 6 with gynaecological cancers (cervical and endometrial), and 2 each included bladder and pancreatic cancers. Most studies (*n* = 18) included less than 100 patients, with 9 studies having less than 50 patients included.Fig. 1Systematic Search OutcomesTable 2All included studiesAuthorYearCancer siteNo of ptsPts with toxOAR studiedToxicity score usedRT TypePrimary RT Dose (Gy/\#)Pelvic RT dose (Gy/\#)Concurrent chemo useAdkison \[[@CR34]\]2012Prostate5320small bowelCTCAE v3.0IMRT70/2856/28noal-Abany \[[@CR18]\]2005Prostate659anal sphincter regionOwn questionnaire3D70.2/39NSnoAlsadius \[[@CR19]\]2012Prostate or prostatic bed40351anal sphincter regionOwn questionnaire3D70/35NSnoBuettner \[[@CR20]\]2012Prostate38857anal canalCommon grading scheme3D64/32 or 74/37NSnoChopra \[[@CR11]\]2014Cervix (post-op)719small bowel, large bowelCTCAE v3.0IG-MRT (46); 3D (25)50/2550/2563/71 cisplatinDeville \[[@CR31]\]2010Prostate302intestinal cavityRTOGIMRT79.2/4445/25noDeville \[[@CR7]\]2012Prostatic bed365intestinal cavityRTOGIMRT70.2/3945/25noEbert \[[@CR35]\]2015Prostate754Symptom specificAnal canalLENT-SOMAIMRT66--78/33--38NSnoFokdal \[[@CR14]\]2005Prostate or bladder71Symptom specificsmall bowelLENT-SOMAConformal60/30 (bladder) 69.6/35 (prostate)48-60Gy bladder; NS for prostate)noFonteyne \[[@CR17]\]2007Prostate241Symptom specificsmall bowel, sigmoidRTOG and "RILIT"IMRT74/37--80/40NSnoGreen \[[@CR36]\]2015Prostate or prostatic bed7310Intestinal cavityCTCAE v4.0IMRT/VMAT61--79.245noGuerrero- Urbano \[[@CR8]\]2010Prostate & Pelvic nodes7921bowel loopsRTOG diarrhoea & LENT SOMA diarrhoeaIMRT70/3550/35 or 55/35noHuang \[[@CR15]\]2011Pancreas468duodenumCTCAE v4.03D or IMRT42/1542/15; 36/15; 38/19Gemcitabine; 18 pts. erlotinib in additionIsohashi \[[@CR10]\]2013Cervix (post-op)9716peritoneal cavity, small and large bowelRTOG/EORTC2D or 3D50/2550/25All nedaplatinKelly \[[@CR13]\]2013Pancreas10620duodenumCTCAE v4.03D or IMRT50.4/28 (78pts); 57.5--75.4 in 28--39\# (28pts)50.4/28 (78pts); 57.5--75.4 in 28--39\# (28pts)Gemcitabine\
5-FUor capecitabine +/− cetuximab or erlotinibAuthorYearCancer siteNo of ptsPts with toxOAR studiedToxicity score usedRT TypeRT Dose (Gy/\#)Pelvic RT dose (Gy/\#)Concurrent chemo useKoper \[[@CR25]\]2004Prostate266141anal canalRTOG (simplified)\
Symptom questionnaire3D or 2D66/33NSnoLind \[[@CR12]\]2016Cervical or Endometrium51963Anal sphincter, small bowel, sigmoidOwn questionnaire (defecation into clothing without forewarning)2D or 3D40--46 (endometrium) or 55--70 (cervix)NSNot statedMavroidis \[[@CR27]\]2005Prostate65Symptom specificanal sphincterOwn questionnaire3D70.2/39NSnoMcdonald \[[@CR9]\]2015Bladder4710bowel loopsRTOG3D64/3264/3221 received 5-FU/MMCMouttet-Audouard \[[@CR6]\]2015Cervical378Small bowel \[defined as peritoneal cavity\], sigmoidCTCAE v4.0IMRT (tomotherapy)60/2850/28CisplatinPeeters \[[@CR21]\]2006Prostate641146Anal wallRTOG/EORTC plus 5 specified symptoms3D (41 pts. had IMRT boost)68/34 or 78/39NSnoPeeters \[[@CR28]\]2006Prostate36832Anal wallIncontinence (no specific questionnaire)3D (22 pts. had boost)68/34 or 78/39NSnoPoorvu \[[@CR16]\]2013Cervix or Endometrium (+ PA nodes)463peritoneal cavity, small bowel, duodenal segmentsCTCAE v4.0IMRT45/25 (22pts); PAN boost 50--65 (33pts)45/25 & PAN boost 50--65 (33 pts)24 received cisplatinSmeenk \[[@CR26]\]2012Prostate4821Anal sphincter musclesPresence of frequency, urgency and incontinence3D (*n* = 43, IMRT (*n* = 5)67.5/27 or 70/28NSnoSmeenk \[[@CR22]\]2012Prostate3623Anal wallLate RILIT score: urgency, incontinence, frequency3D67.5/27 or 70/28NSnoTaussky \[[@CR37]\]2003Prostate73unclearanal canalUCLA, FACT-P and EORTC QLQ-PR253D66.6--72/ 37--40NSnoThor \[[@CR29]\]2015Prostate212Symptom specificAnal sphincterOwn questionnaire with 19 descriptors for 4 symptoms3D70-78GyNSnoVerma \[[@CR30]\]2014Cervix & Endometrium1059duodenumRTOG and endoscopic findingsIMRT45--50 (60-66Gy boost)45--50 (60--66 boost)58 pts. platinum agentsVordermark \[[@CR23]\]2003Prostate or prostatic bed4414% severe incontinenceanal canal10 question continence questionnaire3D58--72/29--36NSNoYeoh \[[@CR24]\]2016Prostate10672%Anal wallLENT-SOMA total score3D66--74.4/ 33--4NSno*Abbreviations*: *Pts* Patients, *OAR* Organs at risk, *RT* Radiotherapy, *Gy* Gray, *\#* Fraction, *NS* Not stated, *CTCAE* Common terminology criteria for adverse events, *RTOG* Radiation therapy oncology group, *LENT-SOMA* Late Effects of Normal Tissue -- Subjective Objective Management Analytical, *RILIT* Radiation induced late intestinal toxicity, *EORTC* European Organisation for Research and Treatment of Cancer, *IG-IMRT* Image-guided intensity modulated radiotherapy, *IMRT* Intensity modulated radiotherapy, *VMAT* Volumetric modulated arc therapy, *PA nodes* Para-aortic nodes, *pts* Patients

Table [3](#Tab3){ref-type="table"} details studies for whole and small bowel, and Table [4](#Tab4){ref-type="table"} those for large bowel. In each table the final two columns indicate the quality assessment criteria of statistical and endpoint considerations as defined in Table [1](#Tab1){ref-type="table"}. If a specific criterion is met its number is noted in the column.Table 3Whole bowel and small bowel studies -- significant findings and quality assessmentQuality AssessmentAuthorOAR studiedOAR definedToxicity definitionPts with toxicitySignificant findingsStatistical criteria met (1--7)Endpoint criteria met (1--3)Deville \[[@CR7]\]Intestinal cavityIntestinal cavity below L4--5RTOG Gr ≥ 15/36 (14%)Toxicity associated with total volume & V20. No constraints specified.1,7\
(n/a: 2--6)NoneMouttet-Audouard \[[@CR6]\]"Small bowel" \[outlined as abdominal cavity hence included in this section\]Entire abdominal cavity including all possible organ locations to iliac crests or D12/L1CTCAE v4.0 Gr1--3 --diarrhoea or "whole digestive toxicity" (diarrhoea, gastritis, bleeding, pain, incontinence)8/37 (21.6%)\
17/37 (46%)Larger volumes of bowel receiving 10--30Gy associated with diarrhoea & whole digestive toxicity. (No constraints specified)\
"Whole digestive toxicity" associated with many parameters including D20%-D95%.1, 7\
(n/a 2--6)2Green \[[@CR36]\]Intestinal cavityNot statedCTCAE v4.09 (12%)No dose-volume relationship found.1 (n/a 2--6)2Deville \[[@CR31]\]Intestinal cavityLarge & small bowel below L4--5RTOG Gr ≥ 22/30 (6%)No dose-volume relationship found1,7\
(n/a 2--6)NoneIsohashi \[[@CR10]\]Peritoneal cavityVolume surrounding small bowel loops to edge of peritoneum excluding bladder & rectumRTOG/EORTC Gr ≥ 216/97 (16.5%)No dose-volume relationship found1,7\
(n/a 2--6)2Poorvu \[[@CR16]\]1. Peritoneum\
2. Peritoneum + Colon1. Possible location of small bowel excluding solid organs & retroperitoneal structures.\
2. Peritoneum (as above) plus asc & desc colonCTCAE v4.0 Gr \> 33/46 (6.5%)No dose-volume relationship found1, 7\
(n/a 2--6)2Guerrero-Urbano \[[@CR8]\]Bowel loopsLoops from recto-sigmoid junction to 2 cm above PTVRTOG Gr ≥ 2 diarrhoea; LENT-SOMA consistency & frequency- worst grade21/79 (26%) RTOG diarrhoea; ≥gr2 6/79 (7.6%)V40, V45, V60 and bowel volume of \> 450 cc had both higher RTOG & LENTSOMA diarrhoea.\
Constraints suggested: V40 \< 124 cc, V45 \< 71 cc, V60 \< 0.5 cc for RTOG\<gr 21,7\
(n/a 2--3)1McDonald \[[@CR9]\]Bowel loopsLoops from recto-sigmoid junction to 2 cm above PTVRTOG Gr ≥ 17/47 (14.9%) gr1; 3/47 (6.4%) gr2Constraints for \< 25% ≥ gr2 toxicity: V30 \< 178 cc;V35 \< 163 cc;V40 \< 151 cc;V45 \< 139c; V50 \< 127 cc; V55 \< 115 cc; V60 \< 98 cc V65 \< 40 cc1,4,7\
(n/a 2--3)2Chopra \[[@CR11]\]Small bowel2 cm above target, individual small bowel loops (unclear how differentiated from large bowel)CTCAE v3.0 Gr3+9/71 (12.6%)V15 associated with ≥gr3 toxicity. Recommend V15 \< 275 cc, V30 \< 190 cc, V40 \< 150 cc reduces Gr3 toxicity from 23.6 to 5.6%.1, 4, 6\
(n/a 2,3)2Isohashi \[[@CR10]\]Small bowelBowel loops remaining after exclusion of large bowel loopsRTOG/EORTC Gr ≥ 216/97 (16.5%)V40 best predictor of late toxicity; Recommend V40 \< 340 ml to reduce toxicity from 46.2 to 8.7%1,4,6,7\
(n/a 2,3)2Lind \[[@CR12]\]Small bowelAll visible small bowel in small pelvic cavity to caudal part of sacroiliac jointsDefecation into clothing without warning \> 1 in last 6 months63/519 (12.1%)Mean dose\>50Gy to small bowel or sigmoid or anal sphincter region associated with symptom (findings for individual organs not clarified)1, 7 (n/a 2,3)1,2,3Adkison \[[@CR34]\]Small bowelNot clearly definedCTCAE v3.0 Gr1 and Gr2Gr1 16/53 (30%); Gr2 4/53 (8%)No dose-volume relationship with V30-V60 small bowel1\
(n/a 2--6)NoneFokdal \[[@CR14]\]Small bowelOpacified & unopacified small intestine loops (outer contour & contents) from 1st slice to minor pelvisLENT-SOMA G1--4Symptom specificNo dose-volume relationship found1,7\
(n/a 2--6)1,2,3Fonteyne \[[@CR17]\]Small bowelNot clearly definedRTOG and "RILIT" Gr1 & Gr2Gr1 112/241 (46%), Gr2 32/241(13%)No dose-volume relationship found1,\
(n/a 2--6)1,2Poorvu \[[@CR16]\]Small bowelOpacified & non-opacified small bowel loopsCTCAE v4.0 Gr3+3/46 (6.5%)No dose-volume relationship found1,7\
(n/a 2--6)2Huang \[[@CR15]\]DuodenumDuodenal bulb to ligament of TreitzCTCAE v4.0 Gr ≥ 38/46 (17.4%)With a V25 \> 45% toxicity rates increase from 8 to 48%1,4,6,7\
(n/a 2,3)2Kelly \[[@CR13]\]DuodenumGastric pylorus until end of duodenum 3 cm past midlineCTCAE v4.0 Gr ≥ 220/106 (18.9%)With a V55 \> 1 cc toxicity rates increase from 9 to 47%1,4,6,7\
(n/a 2,3)2Verma \[[@CR30]\]DuodenumFrom gastric outlet through transverse portion of duodenum (ascending portion excluded)RTOG, all grades9 /105 (8.6%)With a V55 \> 15 cc toxicity rates increase from 7.4 to 48.6%1,4,6,7\
(n/a 2,3)2Poorvu \[[@CR16]\]Duodenal segmentsD1 segment: bulblike shape & origin beyond gastric pylorus. Transitions between 2nd & 3rd segments was lateral border of IVC; Between 3rd & 4th was medial border of aortaCTCAE v4.0 Gr ≥ 33/46 (6.5%)No dose-volume relationship found with duodenum1,7\
(n/a 2--6)2*Abbreviations*: *Pts* Patients, *OAR* Organs at risk, *RT* Radiotherapy, *Gr* Grade, *CTCAE* Common terminology criteria for adverse events, *RTOG* Radiation therapy oncology group, *LENT-SOMA* Late Effects of Normal Tissue -- Subjective Objective Management Analytical, *RILIT* Radiation induced late intestinal toxicity, *EORTC* European Organisation for Research and Treatment of Cancer, *Vx* Volume receiving x Gy, *AUC* Area under curveTable 4Large Bowel studies - details and quality assessmentQuality AssessmentAuthorOAR studiedOAR definedToxicity definitionPts with toxicitySignificant findingsStatistical considerations met (1--7)Endpoint considerations met (1--3)Chopra \[[@CR11]\]Large bowel2 cm above target, individual loops of large bowel (unclear how differentiated from small bowel)CTCAE v3.0 Gr ≥ 39/71 (12.6%)V15 associated with ≥gr 3 toxicity.\
Constraints: V15 \< 250 cc, V30 \< 100 cc, V40 \< 90 cc to reduce toxicity from 26.7 to 5.4%1, 4, 6\
(n/a 2,3)2Isohashi \[[@CR10]\]Large bowelSingle loop continuing from end of sigmoid to ascending colonRTOG/EORTC, Gr ≥ 216/97 (16.5%)No constraint found for large bowel1,7\
(n/a 2--6)2Fonteyne \[[@CR17]\]Sigmoid colonWhere rectum sweeps anteriorly to one slice above aortic bifurcationRTOG and "RILIT" Gr 1 and 2Gr 1112/241 (46%), Gr 2 32/241 (13%).V40 associated with gr1 diarrhoea & blood loss.\
Constraints: V40 \< 10%, V30 \< 16% to avoid gr1--2 diarrhoea1, 7\
(n/a 3)1,2Mouttet-Audouard \[[@CR6]\]Sigmoid colonAnterior curvature of sigmoid colon to anterior abdominal wallCTCAE v4.0\
Gr1--3 diarrhoea and "whole digestive toxicity"8/37 (21.6%) diarrhoea; 17/37\
(46%) (whole tox)'Whole late digestive toxicity' associated with V30--40. No specific constraints.1,7\
(n/a 2--6)1,2Lind \[[@CR12]\]Sigmoid colonFrom where rectum deviates from its mid- position to where it turns cranially in left abdomen connecting to colon descendensDefecation into clothing without warning \> 1 in last 6 months63/519 (12.1%)Mean dose\>50Gy to small bowel or sigmoid or anal sphincter region associated with symptom (findings for individual organs not clarified)1, 7\
(n/a 2--6)1,2,3al-Abany \[[@CR18]\]Anal sphincter regionCaudal 3 cm of the rectum from anal verge (including filling)Own questionnaire; Faecal leakage \>2X/week9/65 (13.8%) faecal leakageIncreased risk with mean dose of 45-55Gy.\
Constraints: V35 \< 60%, V40 \< 40% associated with no risk of faecal leakage.1, 7\
(n/a 2,3)1,2,3Alsadius \[[@CR19]\]Anal sphincter regionCaudal part of large bowel, from end of rectal ampulla where bowel no longer had visible content or air.Own questionnaire;\
Faecal leakage \>once per month51/403 (12.7%) faecal leakageDmean\<40Gy reduces risk from 17 to 4%.1,2,4,7\
(n/a 3)1,2,3Fokdal \[[@CR14]\]Anal canalOuter contour of the structure extending from anal verge 2 cm craniallyLENT SOMA scoreUrge: 27/71 (38%); Incontinence: 21/71 (30%)Urgency related to Dmed\> 33.8: increases toxicity 31 to 47%\
Incontinence related to Dmax\> 53.8 increases 14 to 44%1,2,4,5,7\
(n/a 3)1,2,3Vordermark \[[@CR23]\]Anal canalAnal verge to the section below visible rectal lumen, corresponding to the upper border of the\
levator ani muscle"Solid soiling" (Severe incontinence)\
Own continence questionnaire6/44 (14%)Severe incontinence\
- associated with Dmin (23.1Gy)\
- related to portals extending 2 mm below ischial tuberosities (compared with 5 mm above)1, 7\
(n/a 2--3)1,2,3Koper \[[@CR25]\]Anal canalCaudal 3 cm of the intestineRTOG gr1 + 2;\
Plus symptom questionnaire.141/248 (57%)D90% (=54.9Gy) to associated with ≥ gr1 rectal toxicity1, 7\
(n/a 2--6)2,3Taussky \[[@CR37]\]Anal canalMost distal 2-3 cm of rectum10 questions from UCLA-PCI, FACT-P & EORTC QLQ -PR25Unclearno relation with anal canal DVH found7\
(N/a: 2--3)3Buettner \[[@CR20]\]Anal canalCaudal 3 cm of rectumCommon grading scheme; subjective sphincter control at highest grade57/388 (14.7%)DSH data: Toxicity correlated with dose to anal surface: lateral extent 53Gy \> 56%.\
DVH data: Dmean 47Gy to anal sphincter volume correlated with sphincter toxicity. Constraints: Dmean\<30Gy.NTCP modeling to LKB model TD50 = 120, m = 0.42.1,3,6,7\
(n/a 2)1,2,3Peeters \[[@CR21]\]Anal wallWall of caudal 3 cm of anorectum (method described)RTOG/EORTC ≥ gr 2 and ≥ gr 3 Plus incontinence pad use\>2x/wk.≥gr 2165/641 (25.7%) ≥ gr 3 27/641 4.2%Dmean increase from 19Gy to 52Gy increased gr2 toxicity: 16 to 31%.\
V65 & Dmean most significant for incontinence. Dmean increase by 33Gy increased incontinence by 12%1,2,4,6,7\
(n/a 3)1,2Mavroidis \[[@CR27]\]Anal sphincter regionMusculaure layer around the rectal aperture, 3 cm caudal from anal vergeOwn questionnairefaecal leakage 19/65 (29%); blood/mucus 22/65 (34%)Relative seriality NTCP model of anal sphincter for incontinence, blood/mucus. Parameters for incontinence: *D*50 = 70.2Gy, *γ* = 1.22, *s* = 0.35. Parameters for blood/mucus: *D*50 = 74.0Gy, *γ* = 0.75, *s* ≈ 01, 3, 5, 6, 7\
(n/a 2)1,3Peeters \[[@CR28]\]Anal canal wallWall of caudal 3 cm of anorectum (method described)Incontinence requiring pad\
use\>2x/wk.;32/368 (7%)NTCP LKB model of incontinence with anal wall dose. Parameters found were *n* = 7.48; TD50 = 105; m = 0.461,3,4,5,6,7\
(n/a: 2)1,3Smeenk \[[@CR26]\]Anal sphincter musclesIndividual muscles defined (Internal anal sphincter (IAS), external anal sphincter (EAS), puborectalis & levator ani)Frequency, Urgency, Incontinence21/48 (44%)For complication \<5% Dmean\<30Gy to IAS; \<10Gy to EAS, \< 50Gy to puborectalis, \<40Gy to levator ani1, 4,5\
(n/a 2)1,2,3Smeenk \[[@CR22]\]Anal wallContinuation of rectal wall from anal verge to slice below lowest slice with a rectal balloonFrequency, urgency, incontinence39% frequency, 31% urgency, 31% incontinenceFor urgency:\
Anal wall Dmean\<38Gy risk \< 15%, \>38Gy risk is 62%1,4,7\
(n/a 2,3,5,6)1,3Lind \[[@CR12]\]Anal sphincter regionInner muscle layer of the sphincter up to anal vergeDefecation into clothing without warning \> 1 in last 6 months63/519 (12.1%)Mean dose\>50Gy to small bowel or sigmoid or anal sphincter region associated with this symptom\
(findings for individual organs not clarified)1, 7 (n/a 2,3)1,2,3Yeoh \[[@CR24]\]Anal wallFrom anorectal junction (not clearly defined)LENT-SOMA total score72%Anal wall V40 \> 65% associated with chronic toxicity.1,5 (n/a 2,3)2,3Thor \[[@CR29]\]Anal sphincterAnal canal, inner and outer sphincter (not clearly defined)Questionnaire of 19 questions in 4 domains: pain urgency, mucus & incontinence.Specific to each of 19 question5 LKB models proposed for anal sphincter doses.\
Low anal sphincter dose associated with faecal leakage and pain. High anal sphincter dose associated with leakage.1,3,6 (n/a 2)1,2,3Ebert \[[@CR35]\]Anal CanalCaudal 3 cm of anorectumLENT-SOMA -- 8 symptomsSpecific to each symptomBleeding associated with \>40Gy, proctitis with 36-63Gy, frequency with 8-85Gy, urgency and tenesmus with 5-34Gy to anal canal.1,5,7 (n/a 2)1,2,3*Abbreviations*: *Pts* Patients, *OAR* Organs at risk, *RT* Radiotherapy, *Gr* Grade, *CTCAE* Common terminology criteria for adverse events, *RTOG* Radiation therapy oncology group, *LENT-SOMA* Late Effects of Normal Tissue -- Subjective Objective Management Analytical, *RILIT* Radiation induced late intestinal toxicity, *EORTC* European Organisation for Research and Treatment of Cancer, *Vx* Volume receiving x Gy, *AUC* Area under curve, *Dmean* Mean dose, *Dmax* Maximal dose, *DVH* Dose volume histogram, *DSH* Dose surface histogram, *NTCP* Normal Tissue Complication Probability, *LKB* Lyman Kutcher Burman

Whole bowel {#Sec7}
-----------

Eight papers (including 445 patients) examined the dose-volume relationship of whole bowel either using bowel loops or intestinal/peritoneal cavity as detailed in Table [3](#Tab3){ref-type="table"}.

Peritoneal cavity {#Sec8}
-----------------

Late bowel toxicity was associated with low doses to the peritoneal cavity (V10--30Gy) in 2 studies. Mouttett-Audouard et al. \[[@CR6]\] found, in 37 cervical cancer patients, an association between "bigger volumes" of bowel receiving 10--30Gy and grade 1--3 Common Terminology Criteria Adverse Events (CTCAE) toxicity, although specific cut-offs were not reported. Deville et al. \[[@CR7]\] found that peritoneal cavity volume and V20 were both associated with grade 1 Radiation Therapy Oncology Group (RTOG) toxicity. Again no constraints were derived.

Bowel loops {#Sec9}
-----------

Two studies \[[@CR8], [@CR9]\] investigated bowel loops as an OAR for late toxicity, both with an identical definition of bowel loops. Guerrero-Urbano et al., in 79 patients who had their prostate and pelvic nodes treated, found V40, V45 and V60 bowel loops to be predictive of late grade 2 RTOG-graded diarrhoea. They suggested constraints of V40 \< 124 cc, V45 \< 71 cc and V60 \< 0.5 cc to reduce grade 2 RTOG toxicity, although no complication rates associated with these constraints are detailed. McDonald et al. in their study of 47 bladder cancer patients suggested constraints to reduce the risk of grade ≥ 2 RTOG toxicity to less than 25% (V30 \< 178 cc; V40 \< 151 cc; V45 \< 139 cc; V60 \< 98 cc and V65 \< 40 cc), although it must be noted that only 3 patients within this study had grade 2 toxicity.

Small bowel and its components {#Sec10}
------------------------------

Eleven studies (including 1401 patients) were included in this section, with 6 studies examining small bowel and 4 examining the duodenum, as detailed in Table [3](#Tab3){ref-type="table"}. No papers investigating the ileum or jejunum were found.

Small bowel {#Sec11}
-----------

2 of 6 studies found positive correlations with late bowel toxicities and small bowel volume parameters in cervical cancer patients. However, the positive parameters were different between the studies, with Isohashi et al. \[[@CR10]\] recommending a V40 \< 340 cc, and Chopra et al. \[[@CR11]\] recommending a V15 \< 275 cc. Lind et al. \[[@CR12]\] found that a mean small bowel dose \>50Gy was of significance, however could not clarify whether toxicity was linked specifically to small bowel, sigmoid or anal sphincter dose, making these results difficult to interpret.

Duodenum {#Sec12}
--------

3 of 4 studies found positive correlations between dose-volume parameters and duodenal toxicity. Two studies found V55 to be an important predictor, though with differing constraints. Kelly et al.*,* in 106 pancreatic patients recommending a V55 \< 1 cc \[[@CR13]\] and Verma et al. in 105 gynaecological patients recommending a V55 \< 15 cc \[[@CR14]\]. Huang et al. \[[@CR15]\] found V25 to be the significant predictor for pancreatic cancer patients treated with concurrent gemcitabine; with a V25 \< 45% toxicity rates were 8%, above this constraint toxicity was 48%. Investigation of individual duodenal segments did not reveal any positive findings \[[@CR16]\].

Large bowel and its components {#Sec13}
------------------------------

21 studies (including 5006 patients) were included in this section (see Table [4](#Tab4){ref-type="table"}), with 2 examining large bowel, 3 examining sigmoid and 16 studies examining the anal canal/sphincter region.

Large bowel and sigmoid Colon {#Sec14}
-----------------------------

Chopra et al. \[[@CR11]\] found on multivariate analysis that V15 of large bowel was associated with grade 3 CTCAE toxicity (*p* \< 0.03), and recommended with the use of the constraints-V15 \< 250 cc, V30 \< 100 cc and V40 \< 90 cc grade 3 toxicity could reduce from 26.7 to 5.4%.

For the sigmoid colon Fonteyne et al. \[[@CR17]\] found in 241 prostate patients that sigmoid V40 was associated with grade 1 diarrhoea and blood loss; they recommended V40 \< 10% and V30 \< 16% to avoid grade 1--2 diarrhoea. Mouttet-Aldouard et al. \[[@CR6]\] also found sigmoid V30--40Gy to be significantly correlated (*p* \< 0.006) with "digestive toxicity" although no specific cut-offs were defined.

Anal canal {#Sec15}
----------

15 of 16 studies had positive findings relating dose-volume parameters and Normal Tissue Complication Probability (NTCP) models of the anal canal/sphincter to late toxicity. Most defined the anal canal as the distal 3 cm of rectum.

### Dmean {#Sec16}

5 studies \[[@CR18]--[@CR22]\] found Dmean anal canal or anal sphincter region to be most predictive of toxicity, 4 of faecal incontinence and 1 of faecal urgency, as summarised in Table [5](#Tab5){ref-type="table"}. There was relative consistency in the recommended Dmean constraints between 40-47Gy, despite the OARs being defined slightly differently.Table 5Anal canal Dmean resultsStudyNo of ptsOAREndpointDmean (in EQD2) constraintRisk of endpoint below this constraintRisk of endpoint above this constraintAl-albany \[[@CR18]\]65Anal sphincter regionIncontinence \>2X/week43.28%52%Alsadius \[[@CR19]\]403Anal canalIncontinence \> 1x/month405.2%21%Buettner \[[@CR20]\]388Anal sphincter regionIncontinence: moderate/severe (gr2)47, though \<30Gy ideal5% (approx; read from graph)Smeenk \[[@CR22]\]36Anal canal wallUrgency present41.815%62%Peeters \[[@CR21]\]641Anal canal wallIncontinence requiring pad \>2x/weekNo constraint specified16% at 19Gy31% at 52Gy

### Other dose volume histogram (DVH) and dose-surface histogram (DSH) parameters {#Sec17}

Many other DVH parameters of the anal canal were found to be important, including Dmin \[[@CR23]\], Dmax, Dmedian \[[@CR14]\], V40 \[[@CR24]\], V65 \[[@CR21]\] and V90% dose \[[@CR25]\]; these were all in individual findings with little corroboration between studies. Vordermark et al. also found that the treatment field border was important, with those with a lower border 2 mm below ischial tuberosities more likely to have severe incontinence compared with 5 mm above the ischial tuberosities.

Buettner et al. \[[@CR20]\] also examined incontinence using dose surface maps (DSM) for the anal canal. They found the mean dose to the anal surface and the lateral extent of the DSM to be most correlated with subjective sphincter toxicity. They recommend 45Gy for surface-based mean-dose to the anal canal to reduce toxicity.

### Anal sphincter muscles {#Sec18}

Smeenk et al. \[[@CR26]\] related dose to individual sphincter muscles to urgency, frequency and incontinence. To reduce urgency and incontinence to below 5% they recommended a mean dose \<30Gy to internal anal sphincter, \<10Gy to the external sphincter, \< 50Gy to puborectalis and \< 40Gy to the levator ani muscles.

### Normal tissue complication probability (NTCP) modeling {#Sec19}

Four studies detailed NTCP models for the anal canal \[[@CR20], [@CR27]--[@CR29]\], three of fitting data to a Lyman-Kutcher-Burman (LKB) model. Buettner et al. identified mean-dose anal canal parameters related to grade 2 RTOG toxicity, and Peeters et al. looked at anal wall parameters in relation to faecal incontinence, as detailed in Table [4](#Tab4){ref-type="table"}. Peeters et al. further modified their model to incorporate a previous history of abdominal surgery and found this improved the model fit, suggesting a decreased radiation tolerance for patients with this risk factor. Thor et al. \[[@CR29]\] proposed LKB models for pain, mucus and faecal leakage, although their findings are difficult to use practically as within their study they use data from two different centres, where each toxicity is defined differently between centres. Mavroidis et al. \[[@CR27]\] modelled dose to the anal sphincter region for 'faecal leakage' and 'blood or phlegm' in stools using the relative seriality NTCP model. They recommended a reduction in the biologically effective uniform dose (EUD) to anal sphincter \< 40--45Gy may significantly reduce toxicity.

Quality assessment {#Sec20}
------------------

### Statistical criteria {#Sec21}

Most studies provided information on basic statistical data (29/30) and gave clear definitions of OARs (24/30). Constraints were derived in 16 papers, with associated complication rates stated in 12 papers. Goodness-of-fit was reported in 6 studies, with discriminator statistics reported in 10 papers. For the 4 papers with NTCP models all provided parameter estimates with standard error.

### Endpoint criteria {#Sec22}

Overall toxicity grades rather than individual symptoms were assessed in 13 of 30 studies, with patient-reported outcomes used in 14 studies (13 of which were studies of the anal canal). 21 of the studies looked at co-morbidity to assess its contribution to late toxicity and this was taken into account in multivariate analyses if thought to be associated.

Discussion {#Sec23}
==========

We have systematically reviewed the currently published literature on dose-volume constraints for late bowel toxicity after pelvic radiotherapy, excluding the rectum. We identified 30 studies including 5136 patients. A key finding was consistent dose-volume constraints defined for the anal canal from five studies. For whole bowel loops, small bowel, duodenum, large bowel and sigmoid dose-volume constraints were derived in individual studies, however there was limited validation of these findings in other studies examining the same component of bowel.

Of all the components of bowel studied, most data were available in the 16 studies examining the anal canal or anal sphincter region, and these studies were most conclusive. Statistical and endpoint measures recommended by QUANTEC were met much more frequently in these studies, data of which originated mainly from prostate clinical trials. Fifteen of these sixteen studies used individual symptoms reported by patients rather than an overall toxicity score.

These studies clearly indicate a relationship between dose-volume parameters to the anal canal and faecal incontinence. Dmean was the most significant parameter in five different studies, with a range of doses between 40-47Gy found. From the available data we recommend a constraint Dmean of \<40Gy (in 2Gy fractions) to the anal canal to be included in clinical protocols in order to limit late bowel toxicity, in particular faecal incontinence.

For other components of bowel, the evidence was far less conclusive, as the findings of single studies were not corroborated with others. Possible reasons could be differences in the endpoint studied (i.e toxicity, grade and clinician versus patient-reporting) and differences in the definition of the OARs. Furthermore different studies derive constraints with different aims, with some using constraints to lower the risk of toxicity to a certain level eg. to 5% or to 20%, and others attempt to derive constraints with the aim of no toxicity at all.

For example when considering constraints for bowel loops, both Guerrero-Urbano et al. \[[@CR8]\] and McDonald et al. \[[@CR9]\] derived constraints for V40, V45 and V60 associated with late bowel toxicity. However, the constraints in these studies differed, with one suggesting V40 \< 124 cc, V45 \< 71 cc and V60 \< 0.5 cc, and the other recommending V40 \< 151 cc, V45 \< 139 cc and V60 \< 98 cc, despite the same definition of bowel loops, and use of RTOG scoring. Reasons for these differences could be due to differences in endpoint definition, with one study looking specifically at ≥ grade 2 RTOG diarrhoea, with the other looking at overall RTOG toxicity ≥ grade 1. McDonald et al. determined constraints aiming to reduce the risk of ≥grade 1 toxicity specifically to less than 25%, whereas Guerrero-Urbano et al. found constraints with the aim of reducing ≥grade 2 toxicity, but the level to which this aims to reduce the risk of toxicity is unclear.

A similar lack of consistency was seen for studies focussed on duodenum \[[@CR13], [@CR30]\], large bowel \[[@CR10]\] and sigmoid colon \[[@CR6], [@CR17]\] making it difficult to further recommend constraints for these OARs. Future validation of the published constraints using independent data sets from patients using the same toxicity endpoints, same OAR definitions and the same aim in terms of toxicity reduction, would be a useful next step to improve knowledge on this subject.

Many studies found no correlation with OAR dose parameters and late bowel toxicity at all. This lack of findings could be due to a variety of methodological reasons -- many of the studies were underpowered with only a very small incidence of the defined toxicity, making it difficult to determine the likely predictors of these toxicities in only a handful of patients. Many studies have not collected baseline data and presume the presence of bowel symptoms post-radiotherapy is treatment related, when in fact these symptoms may have been pre-existing, or due to a separate bowel pathology. Further a known issue within the pelvis, is that of organ motion of bowel and its subsection, and the use of a single CT scan to define a highly mobile structure may not be an appropriate approach.

Aside from methodology the reason for lack of positive findings may be in fact that particular OARs may genuinely not have any influence on late toxicity, and rather than dose-volume predictors, other considerations such as inherent radiosensitivity of individual patients, may be the main predictors of toxicity.

For acute bowel toxicity QUANTEC have suggested two constraints: V45 \< 195 cc for peritoneal cavity, and V15 \< 120 cc for small bowel loops. The QUANTEC authors suggest these constraints may be applicable for late bowel toxicity. Some consistency is seen to QUANTEC recommendations within this review with Chopra et al. \[[@CR11]\] finding V15 small bowel loops to be important on multivariate analysis, although their recommended constraint was much higher at V15 \< 275 cc.

For peritoneal cavity, the findings of the studies reviewed do not corroborate with QUANTEC. Three studies found no correlation of peritoneal cavity doses with late toxicity, and the two positive studies found that in fact lower doses to peritoneal cavity of V20 and V10--30 \[[@CR6], [@CR31]\] were predictive of late toxicity. It would be important to validate the significance of these low doses in terms of late toxicity given the increased use of volumetric arc therapy (VMAT) techniques in recent years, where lower dose bath to a larger area of normal tissue is seen, the significance of which is currently not understood.

Strengths of this systematic review are the broad inclusivity of the search, with the studies included having patients with different tumour types, radiotherapy techniques, fractionations, and concurrent treatments. A similar approach was used in key papers such as the Emami et al. data \[[@CR32]\], as well as the QUANTEC papers \[[@CR3], [@CR4]\], where bowel constraints were sought from studies with gynaecological, rectal, prostate and pancreatic cancers. A potential limitation of this is that some of these treatment factors may influence late toxcity (e.g. use of concurrent systemic agents, or hypofractionation). Although it is expected that individual authors may account for these factors statistically this may not have always been done and may explain partly the inconsistent results found.

Despite attempting to be as inclusive as possible we may have missed those studies not in English, and from grey literature currently unpublished. Studies involving SBRT were excluded given the questionable validity of the linear quadratic model with extreme hypofractionation thus making radiobiological comparisons difficult \[[@CR33]\].

Quality assessment based on the QUANTEC-defined criteria added much value to this review, highlighting that many researchers do not report or consider the endpoint or statistical criteria, and further that those that do adhere to these criteria appear to have more conclusive findings.

Conclusions {#Sec24}
===========

We recommend the use of Dmean to the anal canal of \<40Gy in pelvic radiotherapy protocols as a constraint to reduce the development of late bowel toxicity, in particular faecal incontinence.

Other important organs at risk to consider are whole bowel loops, small bowel, duodenum, large bowel and sigmoid colon and constraints for these OARS are noted in this review. However, clear recommendations for these organs cannot be made, due to lack of correlation between studies. Validation of the constraints found within this systematic review for these OARS with independent data sets would be an important next step. If validated these constraints could be used clinically in prospective patients, and also as a relevant benchmark to assess the likely impact of advanced radiotherapy techniques on late toxicity. Future studies should consider the quality criteria recommended by QUANTEC.
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Gy

:   Gray
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:   Lyman-Kutcher Burman

OAR

:   Organ at Risk
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Vx Gy

:   Volume receiving x Gray

Not applicable.

Funding {#FPar1}
=======

This work was supported by Velindre Cancer Centre Charitable Funds, and Cancer Research Wales.

Availability of data and materials {#FPar2}
==================================

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

BC performed all systematic searching. RJ and EH screened all abstracts, and scrutinized relevant full texts and hand-searched for additional references. All authors read and approved the final draft of this manuscript.

Ethics approval and consent to participate {#FPar3}
==========================================

Not applicable.

Consent for publication {#FPar4}
=======================

Not applicable.

Competing interests {#FPar5}
===================

The authors declare they have no competing interests.

Publisher's Note {#FPar6}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
